Zhou Sheng-Yu, Huang Ding-Zhi, Shi Yuan-Kai, He Xiao-Hui, Wu Yao-Huang, Li Ye-Xiong
Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100-021, P.R. China.
Ai Zheng. 2005 Jan;24(1):95-8.
BACKGROUND & OBJECTIVE: Primary thyroid lymphoma (PTL) is a rare disease. It is likely to be misdiagnosed, and its treatment remains controversy. This study was to investigate clinicopathologic features of PTL, and explore proper treatments.
Records of 22 patients with PTL treated in Cancer Hospital, Chinese Academy of Medical Sciences from Jan.1990 to Jan. 2004 were retrospectively analyzed.
Of the 22 patients, 18 were women, 4 were men. The median age is 55 (33-80) years. All patients were B-cell original; according to WHO classification, 16 (72.7%) were diffuse large B-cell lymphoma (DLBCL), and 6 (27.3%) were mucosa associated lymphoid tissue (MALT) lymphoma. Five patients received surgery alone; 7 received radiotherapy after surgery, 6 received chemotherapy after surgery, 4 received chemotherapy and radiotherapy after surgery. With a median follow-up of 42 (1-168) months, 5-year relapse-free survival rate was 34.78%, and 5-year overall survival rate was 37.36%.
PTL typically occurs in women. The majority of PTL is B-cell original; DLBCL, and MALT lymphoma were the most common histological subtypes. Patients with PTL of stage IE or IIE should be treated with surgery-based combined modality.
原发性甲状腺淋巴瘤（PTL）是一种罕见疾病。它很可能被误诊，其治疗仍存在争议。本研究旨在探讨PTL的临床病理特征，并探索合适的治疗方法。
回顾性分析1990年1月至2004年1月在中国医学科学院肿瘤医院接受治疗的22例PTL患者的记录。
22例患者中，18例为女性，4例为男性。中位年龄为55（33 - 80）岁。所有患者均为B细胞起源；根据世界卫生组织分类，16例（72.7%）为弥漫性大B细胞淋巴瘤（DLBCL），6例（27.3%）为黏膜相关淋巴组织（MALT）淋巴瘤。5例患者仅接受手术治疗；7例患者术后接受放疗，6例患者术后接受化疗，4例患者术后接受化疗和放疗。中位随访时间为42（1 - 168）个月，5年无复发生存率为34.78%，5年总生存率为37.36%。
PTL通常发生于女性。大多数PTL为B细胞起源；DLBCL和MALT淋巴瘤是最常见的组织学亚型。IE期或IIE期PTL患者应以手术为主的综合治疗。
Zotero 插件